CN105377879B - 针对衣原体属物种的疫苗 - Google Patents

针对衣原体属物种的疫苗 Download PDF

Info

Publication number
CN105377879B
CN105377879B CN201480026477.5A CN201480026477A CN105377879B CN 105377879 B CN105377879 B CN 105377879B CN 201480026477 A CN201480026477 A CN 201480026477A CN 105377879 B CN105377879 B CN 105377879B
Authority
CN
China
Prior art keywords
amino acid
acid sequence
polypeptide
chlamydia
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480026477.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105377879A (zh
Inventor
弗兰克·福尔曼
艾达·罗森克兰达斯
安雅·奥尔森
彼得·拉瓦茨·安德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Priority to CN202110407442.8A priority Critical patent/CN113185587A/zh
Publication of CN105377879A publication Critical patent/CN105377879A/zh
Application granted granted Critical
Publication of CN105377879B publication Critical patent/CN105377879B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201480026477.5A 2013-03-18 2014-03-17 针对衣原体属物种的疫苗 Active CN105377879B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110407442.8A CN113185587A (zh) 2013-03-18 2014-03-17 针对衣原体属物种的疫苗

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA201300155 2013-03-18
DKPA201300155 2013-03-18
DKPA201300684 2013-12-11
DKPA201300684 2013-12-11
PCT/DK2014/000015 WO2014146663A1 (en) 2013-03-18 2014-03-17 Vaccines against chlamydia sp.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110407442.8A Division CN113185587A (zh) 2013-03-18 2014-03-17 针对衣原体属物种的疫苗

Publications (2)

Publication Number Publication Date
CN105377879A CN105377879A (zh) 2016-03-02
CN105377879B true CN105377879B (zh) 2021-05-04

Family

ID=50639248

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480026477.5A Active CN105377879B (zh) 2013-03-18 2014-03-17 针对衣原体属物种的疫苗
CN202110407442.8A Pending CN113185587A (zh) 2013-03-18 2014-03-17 针对衣原体属物种的疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110407442.8A Pending CN113185587A (zh) 2013-03-18 2014-03-17 针对衣原体属物种的疫苗

Country Status (20)

Country Link
US (4) US20140275478A1 (enExample)
EP (1) EP2976355B1 (enExample)
JP (3) JP2016514713A (enExample)
CN (2) CN105377879B (enExample)
AU (1) AU2014234765B2 (enExample)
BR (1) BR112015023886B1 (enExample)
CA (1) CA2907199C (enExample)
CY (1) CY1122905T1 (enExample)
DK (1) DK2976355T3 (enExample)
ES (1) ES2781579T3 (enExample)
HR (1) HRP20200511T1 (enExample)
HU (1) HUE048573T2 (enExample)
LT (1) LT2976355T (enExample)
PL (1) PL2976355T3 (enExample)
PT (1) PT2976355T (enExample)
RS (1) RS60135B1 (enExample)
RU (1) RU2723046C2 (enExample)
SI (1) SI2976355T1 (enExample)
SM (1) SMT202000160T1 (enExample)
WO (1) WO2014146663A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6952603B2 (ja) 2015-02-10 2021-10-20 オハイオ・ステイト・イノベーション・ファウンデーション クラミジア活性化ｂ細胞プラットフォーム及びその方法
CN104800841B (zh) * 2015-03-02 2019-04-02 中国农业科学院兰州兽医研究所 牦牛流产衣原体灭活疫苗及其制备方法
CA2980227A1 (en) 2015-03-24 2016-09-29 Universiteit Gent A method for the detection of chlamydia suis
AU2016349937B2 (en) * 2015-11-04 2021-09-30 University Of The Sunshine Coast Chlamydia antigens and uses thereof
WO2017083337A1 (en) 2015-11-10 2017-05-18 Ohio State Innovation Foundation Methods and compositions related to accelerated humoral affinity
NL2019320B1 (en) * 2017-03-02 2018-09-21 Biosparq B V Diagnostic method and system for diagnosis
CN110603053A (zh) * 2017-03-23 2019-12-20 俄亥俄州国家创新基金会 重组衣原体活化的b细胞平台及其使用方法
RU2721123C1 (ru) * 2019-09-26 2020-05-18 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Штамм рекомбинантной псевдоаденовирусной частицы, экспрессирующий химерный ген MBL-CT666 Chlamydia trachomatis, способ его получения, иммуногенная композиция для защиты от урогенитального хламидиоза человека
WO2022136508A1 (en) * 2020-12-23 2022-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
CN116854812B (zh) * 2022-03-23 2024-09-24 东莞市朋志生物科技有限公司 抗沙眼衣原体的抗体、检测沙眼衣原体的试剂和试剂盒
CN115975049A (zh) * 2022-11-12 2023-04-18 北京成大天和生物科技有限公司 一种沙眼衣原体重组蛋白及其制备方法和应用
AR132053A1 (es) * 2023-03-02 2025-05-21 Sanofi Pasteur Composiciones para su uso en el tratamiento de clamidia
WO2025104023A1 (en) 2023-11-13 2025-05-22 Ziphius Nv MODIFIED ALPHAVIRAL nsP3

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869608A (en) * 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
WO2012172042A1 (en) * 2011-06-17 2012-12-20 Universiteit Gent Vaccines for chlamydia

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5837268A (en) * 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
GB9215780D0 (en) * 1992-07-24 1992-09-09 Univ London Pharmacy Peptide compounds
DE69322645T2 (de) * 1992-07-31 1999-05-20 Medeva Holdings B.V., Amsterdam Expression rekombinanter fusionsproteine in attenuierten bakterien
AU669000B2 (en) 1992-09-18 1996-05-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Synthetic peptide vaccine for chlamydia trachomatis
GB9516293D0 (en) * 1995-08-09 1995-10-11 Immunova Ltee Novel peptides and their use as vaccines
JP2002512622A (ja) * 1997-05-06 2002-04-23 バンダービルト ユニバーシティー クラミジアにより引き起こされる感染の診断および管理のための抗クラミジア剤の組成物
WO2002051430A2 (en) * 2000-12-22 2002-07-04 Synovis Limited Methods of modulating toll-related receptor (trr) signaling
US7105171B2 (en) 2002-03-07 2006-09-12 The Regents Of The University Of California Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
MXPA05013260A (es) * 2003-06-26 2006-03-09 Chiron Corp Composiciones inmunogenicas para chlamydia trachomatis.
EP2269636A3 (en) * 2004-10-25 2011-04-06 Statens Serum Institut Chlamydia trachomatis antigens for vaccine and diagnostic use
WO2006125076A2 (en) * 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
TW201012929A (en) * 2008-09-29 2010-04-01 Univ Nat Pingtung Sci & Tech A hybridoma cell line producing monoclonal antibodies against chalmydophila aborts
EP2413959A4 (en) * 2009-01-29 2013-06-19 British Columbia Cancer Agency CHLAMYDIA-ANTIGENE COMPREHENSIVE COMPOSITIONS
US8735543B2 (en) * 2010-05-28 2014-05-27 Spixia Biotechnology Ab Chimeric MOMP antigen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869608A (en) * 1989-03-17 1999-02-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and amino acid sequences of the four variable domains of the major outer membrane proteins of Chlamydia trachomatis
WO2012172042A1 (en) * 2011-06-17 2012-12-20 Universiteit Gent Vaccines for chlamydia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Detection of Chlamydia trachomatis-specific antibodies in human sera by recombinant major outer-membrane protein polyantigens;Per Mygind等;《Journal of Medical Microbiology》;20000630;第49卷(第5期);摘要，图2(b) *
Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1;Wen Xu等;《Vaccine》;20110212;摘要，材料与方法2.3 HPV6bL1-Ct MOMP多表位质粒的构建 *
Vaccination with the Recombinant Major Outer Membrane Protein Elicits Antibodies to the Constant Domains and Induces Cross-Serovar Protection against Intranasal Challenge with Chlamydia trachomatis;Delia F. Tifrea等;《Infection and immunity》;20130311;第81卷(第5期);摘要 *

Also Published As

Publication number Publication date
EP2976355A1 (en) 2016-01-27
CN113185587A (zh) 2021-07-30
JP7506930B2 (ja) 2024-06-27
RS60135B1 (sr) 2020-05-29
US20210205433A1 (en) 2021-07-08
AU2014234765A1 (en) 2015-10-08
US10925954B2 (en) 2021-02-23
RU2723046C2 (ru) 2020-06-08
JP7510142B2 (ja) 2024-07-03
HRP20200511T1 (hr) 2020-06-26
SI2976355T1 (sl) 2020-07-31
PT2976355T (pt) 2020-04-02
US20190099478A1 (en) 2019-04-04
SMT202000160T1 (it) 2020-05-08
JP2016514713A (ja) 2016-05-23
ES2781579T3 (es) 2020-09-03
JP2021193123A (ja) 2021-12-23
BR112015023886A2 (pt) 2017-10-24
LT2976355T (lt) 2020-04-10
BR112015023886B1 (pt) 2023-05-16
AU2014234765B2 (en) 2018-01-25
CN105377879A (zh) 2016-03-02
JP2019163253A (ja) 2019-09-26
CA2907199A1 (en) 2014-09-25
RU2015141214A (ru) 2017-04-26
DK2976355T3 (en) 2020-03-30
CY1122905T1 (el) 2021-10-29
US20250255951A1 (en) 2025-08-14
CA2907199C (en) 2023-10-17
US20140275478A1 (en) 2014-09-18
HUE048573T2 (hu) 2020-08-28
WO2014146663A1 (en) 2014-09-25
PL2976355T3 (pl) 2020-07-13
EP2976355B1 (en) 2020-01-01

Similar Documents

Publication Publication Date Title
CN105377879B (zh) 针对衣原体属物种的疫苗
de la Maza et al. Chlamydia trachomatis vaccines for genital infections: where are we and how far is there to go?
Jiang et al. Evaluation of tandem Chlamydia trachomatis MOMP multi-epitopes vaccine in BALB/c mice model
de la Maza et al. Update on Chlamydia trachomatis vaccinology
JP7641512B2 (ja) Ｔｌｒ７アゴニストにカップリングする新規コロナウイルスポリペプチドワクチンおよびその適用
Toobak et al. Immune response variations to Salmonella enterica serovar Typhi recombinant porin proteins in mice
JP7072921B2 (ja) Ａ群レンサ球菌ワクチン
JP2009515831A (ja) ペスト菌（Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ）抗原を含む組成物
US20180214534A1 (en) Novel targets of acinetobacter baumannii
CN116063548B (zh) 一种融合蛋白KP-Ag1及其用作肺炎克雷伯菌疫苗抗原的应用
WO2022003119A1 (en) Cross-reactive coronavirus vaccine
Pal et al. A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge
Wang et al. Evaluation of a tandem Chlamydia psittaci Pgp3 multiepitope peptide vaccine against a pulmonary chlamydial challenge in mice
AU6653096A (en) Hybrid protein comprising t-helper cell stimulating epitopes and b-cell epitopes from the major outer membrane protein of chlamydia trachomatis and its use as a vaccine
WO2012126149A1 (zh) 结核杆菌融合蛋白及其制备方法和应用
Cheng et al. Assessment of the role in protection and pathogenesis of the Chlamydia muridarum V-type ATP synthase subunit A (AtpA)(TC0582)
US9987346B2 (en) Methods and compositions for vaccinating a subject for a sexually transmitted pathogen
Olsen et al. Publisher Correction: A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars.
CN111948387A (zh) 结核分枝杆菌抗原蛋白Rv1485在制备结核疫苗中的应用
Chanda et al. Bridging Gaps in Antibody Responses and Animal Welfare: Assessing Blood Collection Methods and Vaginal Immunity in Mice Immunized with Intranasal Gonococcal Vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Copenhagen, Denmark

Applicant after: National Serum Institute

Address before: Copenhagen, Denmark

Applicant before: Statens Seruminstitut

COR Change of bibliographic data
GR01 Patent grant
GR01 Patent grant